Trade ZYME stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Zymeworks Inc. (ZYME) is trading at US$26.14, down 2.68% today as of Nov 20, 16:00 EST. The company has a market capitalisation of US$1.96B. Over the past 52 weeks, ZYME has traded between US$21.52 and US$31.97. On Syfe you can trade ZYME with $0 commission and add it to your watchlist.
| Previous close | US$26.86 |
|---|---|
| Market cap | US$1.96B |
| P/E ratio | 34.72 |
| 52-week range | US$21.52 – US$31.97 |
| Volume | 738.81K |
| Exchange | US |
Zymeworks Inc.
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Year: 2017
Zymeworks Inc. (ZYME) stock is trading at US$26.14, -2.68% from the previous close of US$26.86.
The market cap for Zymeworks Inc. (ZYME) stock is approximately US$1.96B.
The price-to-earnings ratio for Zymeworks Inc. (ZYME) is 34.72, based on the latest reported earnings.
The 52-week high for Zymeworks Inc. (ZYME) stock is US$31.97.
The 52-week low for Zymeworks Inc. (ZYME) stock is US$21.52.
Zymeworks Inc. (ZYME) does not currently pay a dividend.
Stay on top of ZYME
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore